InsiderTradr

IXICO plc (IXI.L)

LSE · GBp · Healthcare · Biotechnology

£11.75 (+14.63%) as of

Key statistics

Market cap
25.73M
Forward P/E
-9.04
EPS (TTM)
-0.02
Dividend yield
0.00%
52-week range
6.26 – 13.00
Beta
0.14
Revenue (TTM)
7.28M
Profit margin
-24.98%
Analyst target
£26.00
Volume
703.94k

About IXICO plc

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Headquarters
London, United Kingdom
Employees
79

ixico.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks